Swarmer Inc. shares skyrocketed 700% on Tuesday, putting the artificial intelligence drone software maker on pace for the best trading debut by a US stock since Newsmax Inc.’s blockbuster entry nearly ...

Himax (HIMX) stock thesis: rumored NVIDIA/Apple ties, TSMC Coupe energy-saving AI data center tech, and 2026 smart glasses ...

Detailed price information for Hamilton Gold Producer Yld Maximizer ETF (AMAX-T) from The Globe and Mail including charting and trades.

The hedge fund owns shares in several notable companies, including Alphabet, Meta, Amazon, and Uber, according to an S-1 filing with the SEC.

Pershing Square Inc. filed for an initial public offering, in a deal that would see billionaire Bill Ackman’s hedge fund make its debut on a US exchange alongside a new closed-end fund.

Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician (CMT). Thomas J. Brock is a CFA and CPA with more than 20 years of experience in ...

Our AI models have generated three distinct trading strategies tailored to different risk profiles and holding periods. Each strategy incorporates sophisticated risk management parameters designed to ...

A trio of US intermediaries have announced growth and acquisition moves spanning group captives, personal lines distribution and integrated P&C advisory, as brokers continue to sharpen their offerings ...

The last few weeks have been rough for newly public York Space Systems. But some analysts see plenty of room for the company to become a space-industry titan — and for its stock to surge. York YSS ...

The strikes come at a precarious time for stocks, forcing investors to weigh the fallout of a potential prolonged disruption to oil supplies and logistics. Note: Data delayed at least 15 minutes.

Stocks slumped on Monday as jittery investors digested President Trump's plan to raise global tariffs to 15% and amid renewed concerns about the impact of artificial intelligence apps on the ...

Novo Nordisk’s experimental weekly shot CagriSema was shown to lead to less dramatic weight loss compared to rival Lilly’s Tirzepatide, the drug behind Zepbound and Mounjaro, in an 84-week trial, Novo ...